Pricing & Reimbursement

As Medicare drug price negotiations creep closer to reality, industry leaders are turning attention to the challenges of implementation and commercial concerns.

Medicare price renegotiation and the FTC’s scrutiny of biopharma acquisitions have suppressed sector stock prices. But the sector may not be the actual target.

An infographic looking at commercial factors for the 10 drugs chosen for Medicare price negotiation in 2026 under the Inflation Reduction Act (IRA). The graphics below review the valuations of these drugs, both past and forecast, as well as their relative contributions to the top-lines of the companies that own them.

Novo Nordisk has just become Europe’s most valuable company based on Wegovy’s huge success so far and future potential - but just how big could the obesity market get?

Within a month of obtaining its global first approval in China, Hua Medicine's dorzagliatin is already available in hospitals. What was behind the successful launch of the first-in-class diabetes agent, what are reimbursement plans and how will local commercialization partner Bayer help? Founder and CEO Li Chen sits down to discuss these and other strategies.

The Class of ’26 of Medicare Price Negotiation University is now on stage. Our infographic profiles who they are and where they come from, breaking down the $50.5B in gross annual Part D spending, about 20% of the total.

Big pharma valuations mostly held steady as CMS released its list of the first 10 drugs subject to Medicare negotiations under the Inflation Reduction Act, which held few surprises and included products nearing the end of their patent lives by the time negotiated pricing takes effect.

US Secretary of Commerce Gina Raimondo has made the first official visit to China by a US commerce official in three years, paving the way to possible improvements in bilateral relations. Despite ongoing geopolitical tensions as a major concern for US firms in China, some are returning to growth in the country. 

Firm leans into allegations that the US government violated the Administrative Procedures Act in implementing the program. More legal actions are expected from industry once CMS announces the first list of drugs subject to negotiation. Our lawsuit tracker will keep you apprised.

CVS Health’s new subsidiary Cordavis will help manufacturers produce and/or commercialize biosimilars with the aim of reducing overall drug costs while improving access to and affordability of medicines.

Large employer plan sponsors split on whether to cover GLP-1 drugs for weight loss, according to a recent survey.

New norms call for generics-only prescriptions and prohibits doctors from engaging in third-party educational activity backed by pharma in India. Will pharma need to rethink its branded generics strategy in India or is a tempering/deferment of the norms on the cards?

With a new suit from Boehringer Ingelheim and a consolidated schedule for other cases, the legal threats to the US Medicare drug price negotiation program mandated under the Inflation Reduction Act (IRA) become clearer. Our tracker keeps you apprised of the latest developments.

The commercial and clinical successes of Lilly and Novo's respective GLP-1 receptor agonists provided an explosive finale to the second-quarter earnings season but also raised questions on reimbursement.

Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.

Highly anticipated list will determine the Medicare Part D drugs subject to negotiated prices in 2026. Under the law, the list cannot be subject to administrative or judicial review, so the stakes are high. As patent and sales statuses shift, Scrip offers a baker's dozen of possible drugs.